Reportlinker Adds Pipeline and Commercial Insight: Psoriasis - Established brands challenged by new therapies

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pipeline and Commercial Insight: Psoriasis - Established brands challenged by new therapies

http://www.reportlinker.com/p0360251/Pipeline-and-Commercial-Insight-Psoriasis---Established-brands-challenged-by-new-therapies.html

Introduction

In this report, Datamonitor assesses the main events which shaped the psoriasis market in the past five years, and speculates on major events set to impact over the next ten years. Datamonitor focuses on pipeline and brand dynamics, and generates 10-year brand forecasts. In addition, key prescribing drivers are discussed, as well as unmet needs from the dermatologist and patient perspective.

Features and benefits

* Gain insight into market potential including a robust 10-year epidemiology forecast, commercial opportunity assessment, and unmet need evaluation* Evaluate dynamics within the major psoriasis drug classes, including assessment of dermatologists' key prescribing influences* Assess 10-year indication-specific forecasts, by formulation, for over 50 products, with a clinical and commercial assessment of five pipeline agents.* Enhance understanding of future product potential, with key opinion leader views of late stage agents in the pipeline.

Highlights

Stelara (ustekinumab) is set challenge market leader Enbrel (etanercept) and growing brand Humira (adalimumab), based on better efficacy and dosing. With increasing enthusiasm among physicians, Stelara could take first-line lead by 2012, provided safety remains in check. Datamonitor forecast sales of $828m by 2019. Datamonitor identified 99 products across all stages of psoriasis development. Despite several me-too products, there is considerable focus on new interleukin targets. Stelara has paved the way, but Abbott's briakinumab (ABT-874), the second in class IL-12/23 agent, could be a contender. However, key opinion leaders remain reserved over safety. Tasocitinib (CP-690,550; Pfizer) could potentially fulfill the high unmet need for a safe, effective oral drug. Phase II efficacy data stack up positively for the brand, which threatens oral therapies and potentially biologics if a Phase III head-to-head trial with Enbrel proves positive. However, long-term safety data in psoriasis are needed.

Your key questions answered

* Which brands and late-stage pipeline products will drive growth in the seven major psoriasis markets over the next decade?* Will IL-12/23 antibody Stelara move ahead of leading TNF inhibitors Enbrel and Humira to become the first-line, go-to biologic?* How commercially attractive is Abbott's briakinumab (ABT-874) and how will safety concerns impact uptake?* To what extent will Pfizer's novel small molecule JAK inhibitor tasocitinib (CP-690,550) challenge the biologics in psoriasis therapy?* Will any products challenge LeoPharma's dominance in the topical therapy segment?

To order this report:

: Pipeline and Commercial Insight: Psoriasis - Established brands challenged by new therapies

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker